Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.

Br J Cancer · 2006 · PMC2361294 · PMID 16641916

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, Dank et al (2005) reported that irinotecan plus 5-FU/folinic acid showed a trend to TTP superiority, compared with cisplatin and 5-FU, as well as a better safety profile in a randomised phase III trial.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.